Our article summarizes the results of recent research on the use of soft nanoparticles for delivering nucleic acids to tumor cells for RNA-based therapy. The first part of the article describes advances in the development, as well as the advantages and disadvantages of using lipid nanocarriers, and the second part describes the same for polymeric nanocarriers. The third part presents data on ongoing preclinical and clinical trials of soft nanoparticles (June 2025).
- Victoriya Zhogla
- Viktar Abashkin
- Xiangyang Shi